Canine cognitive dysfunction (CCD) is a neurodegenerative condition affecting aging dogs, marked by disorientation, altered interactions, sleep-wake disturbances, house soiling, and anxiety. Despite its prevalence, CCD remains underdiagnosed, primarily due to the absence of reliable diagnostic tools and limited treatment options. Kim & Hao (2025) provide a timely review of new strategies aimed at improving both diagnosis and therapy.
The authors emphasize that CCD shares several neuropathological features with Alzheimer’s disease, including β-amyloid accumulation, τ protein phosphorylation, neuronal loss, and chronic neuroinflammation. Two major forms of β-amyloid deposition—extracellular amyloid plaques and cerebral amyloid angiopathy—are highlighted as critical contributors to synaptic dysfunction, neurotoxicity, vascular impairment, and progressive cognitive decline.
Advances in diagnostic methods include neuroimaging approaches, biomarker identification, and behavioral assessment tools designed to detect early cognitive changes. On the therapeutic side, interventions targeting β-amyloid deposition, neuroinflammation, and oxidative stress are being developed. These approaches, combined with environmental enrichment and supportive care, show promise in slowing disease progression.
Importantly, the review situates CCD as a valuable translational model for human Alzheimer’s research. By identifying shared mechanisms between the two disorders, new therapeutic strategies may emerge that benefit both canine and human patients.
This synthesis underscores the importance of cross-species research in tackling neurodegenerative diseases, bridging veterinary and human medicine in the quest for effective treatments.
Source: Kim, S. H., & Hao, J. (2025). Recent advances in diagnostic and therapeutic strategies for canine cognitive dysfunction. American Journal of Veterinary Research, 1–8.
